Dong Linda 4

What Happened

• Linda Dong, a director of Fulgent Genetics, received a grant of 11,117 restricted stock units (RSUs) on May 14, 2026. The Form 4 reports an acquisition price of $0.00 per share (i.e., no cash paid at grant) for a total reported cash value of $0 on the filing.
• This was an equity award (not an open‑market purchase or sale) and represents future entitlement to shares subject to vesting rather than an immediate change in marketable holdings.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (appears timely).
• Grant: 11,117 RSUs at $0.00 per share (reported acquisition value $0).
• Shares owned after the transaction: Not disclosed in the provided filing excerpt.
• Footnote: RSUs vest over four years — 1/4 vest 12 months after May 14, 2026, then 1/16th vest every three months over the remaining 36 months, subject to continued service (see F1).
• Transaction type code: A (award/grant).

Context

• RSU grants are common compensation for directors and align incentives with shareholders; they are not an immediate cash investment or open‑market buy. Vesting conditions mean the recipient only receives actual shares over time if service requirements are met.
• This filing documents the award itself and does not indicate any immediate sale or purchase in the market.